{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:10:51Z","timestamp":1792804251724,"version":"4.5.0"},"reference-count":53,"publisher":"American Society for Clinical Investigation","issue":"24","funder":[{"name":"NCATS, NIDDK, NIEHS, NICHD, EPA","award":["P30ES07033,5UH3TR000504,UG3TR002158,R01HD092659,83573801"],"award-info":[{"award-number":["P30ES07033,5UH3TR000504,UG3TR002158,R01HD092659,83573801"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,20]]},"abstract":"<jats:p>\n                    Drug-induced kidney injury, largely caused by proximal tubular intoxicants, limits development and clinical use of new and approved drugs. Assessing preclinical nephrotoxicity relies on animal models that are frequently insensitive; thus, potentially novel techniques \u2014 including human microphysiological systems, or \u201corgans on chips\u201d \u2014 are proposed to accelerate drug development and predict safety. Polymyxins are potent antibiotics against multidrug-resistant microorganisms; however, clinical use remains restricted because of high risk of nephrotoxicity and limited understanding of toxicological mechanisms. To mitigate risks, structural analogs of polymyxins (NAB739 and NAB741) are currently in clinical development. Using a microphysiological system to model human kidney proximal tubule, we exposed cells to polymyxin B (PMB) and observed significant increases of injury signals, including kidney injury molecule-1 KIM-1and a panel of injury-associated miRNAs (each\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.001). Surprisingly, transcriptional profiling identified cholesterol biosynthesis as the primary cellular pathway induced by PMB (\n                    <jats:italic>P<\/jats:italic>\n                    = 1.22 \u00d710\n                    <jats:sup>\u201316<\/jats:sup>\n                    ), and effluent cholesterol concentrations were significantly increased after exposure (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.01). Additionally, we observed no upregulation of the nuclear factor (erythroid derived-2)\u2013like 2 pathway, despite this being a common pathway upregulated in response to proximal tubule toxicants. In contrast with PMB exposure, minimal changes in gene expression, injury biomarkers, and cholesterol concentrations were observed in response to NAB739 and NAB741. Our findings demonstrate the preclinical safety of NAB739 and NAB741 and reveal cholesterol biosynthesis as a potentially novel pathway for PMB-induced injury. To our knowledge, this is the first demonstration of a human-on-chip platform used for simultaneous safety testing of new chemical entities and defining unique toxicological pathway responses of an FDA-approved molecule.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.123673","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T11:02:38Z","timestamp":1545217358000},"source":"Crossref","is-referenced-by-count":85,"title":["Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity"],"prefix":"10.1172","volume":"3","author":[{"given":"Elijah J.","family":"Weber","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Lidberg","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Environmental and Occupational Health Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo K.","family":"Bammler","sequence":"additional","affiliation":[{"name":"Department of Environmental and Occupational Health Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Department of Environmental and Occupational Health Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mavis J.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Redhair","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Atkins","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Hines","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josi","family":"Herron","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatriz","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-5620","authenticated-orcid":true,"given":"Susanne","family":"Ramm","sequence":"additional","affiliation":[{"name":"Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-0560","authenticated-orcid":true,"given":"Martti","family":"Vaara","sequence":"additional","affiliation":[{"name":"Northern Antibiotics Ltd., Espoo, Finland."},{"name":"Division of Clinical Microbiology, Helsinki University Hospital, Helsinki, Finland."},{"name":"Department of Bacteriology and Immunology, Helsinki University Medical School, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Vaara","sequence":"additional","affiliation":[{"name":"Northern Antibiotics Ltd., Espoo, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Himmelfarb","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Kidney Research Institute, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-9313","authenticated-orcid":true,"given":"Edward J.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1116-1197"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1537"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.46.070177.003451"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.13.39"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/jp064757+"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/cc3995"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.01.015"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00280-12"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku441"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit334"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv340"},{"issue":"4","key":"B12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02391-16","article-title":"Role of renal drug exposure in polymyxin B-Induced nephrotoxicity","volume":"61","author":"Manchandani","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp331"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2012.03.033"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00405-08"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks438"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.005"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/med.21494"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01439-09"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx394"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/ac504516k"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02587-12"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015010060"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.06.011"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-012-1163-2"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-2333(97)00113-6"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200562200"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00433.x"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34487"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75417"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161057"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw077"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.03.016"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2017.09.013"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02440311"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02557-14"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118176"},{"issue":"11","key":"B38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01735-17","article-title":"Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity","volume":"61","author":"Babic","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kft247"},{"key":"B40","unstructured":"Spero Therapeutics. IV antibiotics potentiator platform for treating MDR gram-negative infections in the hospital. Spero website. https:\/\/sperotherapeutics.com\/pipeline\/spr741-spr206-iv-potentiator-platform\/ Accessed November 11, 2018"},{"issue":"22","key":"B41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95978","article-title":"Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity","volume":"2","author":"Chang","year":"2017","journal-title":"JCI Insight"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2011.09.005"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1039\/C5LC00392J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01696"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M014498"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M018366"},{"issue":"6","key":"B47","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.bbalip.2012.03.001","article-title":"7-Dehydrocholesterol-derived oxysterols and retinal degeneration in a rat model of Smith-Lemli-Opitz syndrome","volume":"1821","author":"Xu","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.D043877"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bti270"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv412"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-7-261","article-title":"Empirical array quality weights in the analysis of microarray data","volume":"7","author":"Ritchie","year":"2006","journal-title":"BMC Bioinformatics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/123673\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:35:24Z","timestamp":1779194124000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/123673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,20]]},"references-count":53,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2018,12,20]]},"published-print":{"date-parts":[[2018,12,20]]}},"alternative-id":["10.1172\/jci.insight.123673"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.123673","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,20]]},"article-number":"e123673"}}